December 10, 2019 Non Regulatory LIDDS: Update of News Release sent on November 9, 2019, with PDF-file: New Company Update and Market Valuation from Redeye
December 2, 2019 Non Regulatory LIDDS Interview with the LPC-004 study investigator, Professor Laurence Klotz, about the LIDDS Liproca® Depot Phase IIb study results
September 24, 2019 Non Regulatory LIDDS: Wikow Invest is still the biggest shareholder in LIDDS (publ)
August 28, 2019 Non Regulatory LIDDS: Liproca® Depot Phase IIb results to be presented as “Late Breaking News” at EMUC in Vienna on November 16, 2019
March 13, 2019 Non Regulatory LIDDS: First patient receives intratumoral NanoZolid®-docetaxel in Phase I study
March 6, 2019 Non Regulatory LIDDS: Final patient enrolled in Phase IIb Liproca® Depot prostate cancer study
February 5, 2019 Non Regulatory LIDDS adds another Scandinavian clinic to the NZ-DTX-001 clinical trial
February 4, 2019 Non Regulatory LIDDS research activities in intratumoral immunotherapy are in line with leading oncology expert recommendations